rhodioloside has been researched along with Pancreatic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pingping, H; Qinglin, H; Shangzhu, L; Yuetong, L | 1 |
| Chen, X; Kou, Y; Lu, Y; Pu, Y | 1 |
2 other study(ies) available for rhodioloside and Pancreatic Neoplasms
| Article | Year |
|---|---|
Salidroside inhibits proliferation, migration and invasion of human pancreatic cancer PANC1 and SW1990 cells through the AKT and ERK signaling pathway.
Topics: Antineoplastic Agents, Phytogenic; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Glucosides; Humans; MAP Kinase Signaling System; Neoplasm Invasiveness; Pancreatic Neoplasms; Phenols; Proto-Oncogene Proteins c-akt; Signal Transduction | 2020 |
Salidroside ameliorated hypoxia-induced tumorigenesis of BxPC-3 cells via downregulating hypoxia-inducible factor (HIF)-1α and LOXL2.
Topics: Amino Acid Oxidoreductases; Animals; Antineoplastic Agents; Cadherins; Carcinogenesis; Cell Hypoxia; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Disulfides; Down-Regulation; Gene Expression Regulation, Neoplastic; Glucosides; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Transplantation; Pancreatic Neoplasms; Phenols; Sulfonamides | 2020 |